Standout Papers

Semaglutide and ... 2014 2026 2018 2022 386
  1. Semaglutide and NT-proBNP in Obesity-Related HFpEF (2024)
    Mark C. Petrie, Barry A. Borlaug et al. Journal of the American College of Cardiology
  2. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure (2017)
    Milton Packer, Stefan D. Anker et al. JAMA Cardiology
  3. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction (2015)
    Mihai Gheorghiade, Stephen J. Greene et al. JAMA
  4. Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction (2014)
    Robert J. Mentz, Jacob P. Kelly et al. Journal of the American College of Cardiology
  5. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction (2021)
    Javed Butler, Milton Packer et al. European Heart Journal
  6. Mitochondrial function as a therapeutic target in heart failure (2016)
    David A. Brown, Justin B. Perry et al. Nature Reviews Cardiology
  7. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America (2016)
    Clyde W. Yancy, Mariell Jessup et al. Circulation
  8. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction (2020)
    Paul W. Armstrong, Carolyn S.P. Lam et al. JAMA
  9. The Sympathetic Nervous System in Heart Failure (2009)
    Filippos Triposkiadis, George Karayannis et al. Journal of the American College of Cardiology
  10. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction (2020)
    Paul W. Armstrong, Burkert Pieske et al. New England Journal of Medicine

Immediate Impact

3 from Science/Nature 90 standout
Sub-graph 1 of 16

Citing Papers

Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
2025 Standout
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
2024 Standout
5 intermediate papers

Works of Javed Butler being referenced

Semaglutide and NT-proBNP in Obesity-Related HFpEF
2024 Standout
Diuretic Use and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Insights from the VICTORIA Trial
2024
and 7 more

Author Peers

Author Last Decade Papers Cites
Javed Butler 11041 2366 2599 398 15.3k
Robert J. Mentz 9487 2247 4051 563 14.9k
Inder S. Anand 17182 2937 2573 412 22.5k
Muthiah Vaduganathan 11772 2232 3741 609 17.9k
Eldrin F. Lewis 7163 2144 3182 216 16.1k
Wiek H. van Gilst 11707 1436 2395 476 20.5k
Brian Claggett 11841 2989 3761 536 18.4k
Justin A. Ezekowitz 10901 1785 1477 402 15.2k
Frank Ruschitzka 9476 1898 1380 375 14.6k
Akshay S. Desai 16262 3747 4472 379 20.2k
Chim C. Lang 8548 1639 2916 382 15.5k

All Works

Loading papers...

Rankless by CCL
2026